Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus
复制标题
DOI：
10.1007/s00595-016-1338-0
复制
发表时间：
2016
期刊：
影响因子：
2.5
通讯作者：
T. Ojima;M. Nakamori;Masaki Nakamura;M. Katsuda;K. Hayata;Yasushi Nakamura;H. Yamaue
中科院分区：
文献类型：
--
作者：
T. Ojima;M. Nakamori;Masaki Nakamura;M. Katsuda;K. Hayata;Yasushi Nakamura;H. Yamaue
PurposeThe的目的是本研究的目的是确定与化疗疗效和长期生存的晚期食管鳞状细胞癌（SCCE）的患者接受新辅助化疗多西他赛和顺铂加5-氟尿嘧啶（NAC-DCF）的生物标志物。NAC-DCF作为II期研究（UMIN 000007408）进行。切除修复交叉互补基因1（ERCC 1）、III类β-微管蛋白、乳腺癌易感基因I（BRCA 1）、结果多因素Logistic回归分析表明，ERCC 1低表达的肿瘤与病理学反应显著相关（P= 0.016）和BRCA 1高表达的肿瘤（P= 0.030）。多变量考克斯比例风险模型分析显示，高BRCA 1表达（P= 0.031，风险比4.39）的因素与survival.ConclusionsLow ERCC 1表达和高BRCA 1表达的SCCE患者化疗疗效的相关生物标志物。BRCA 1高表达被认为是与生存相关的因素。这些发现可能有助于定制化疗。
PurposeThe aim of this study was to identify the biomarkers associated with chemotherapeutic efficacy and long-term survival for patients with advanced squamous cell carcinoma of the esophagus (SCCE) who had received neoadjuvant chemotherapy with docetaxel and cisplatin plus 5-fluorouracil (NAC-DCF).MethodsThis study included 45 patients with advanced SCCE who received NAC-DCF between 2008 and 2012. The NAC-DCF was conducted as a phase II study (UMIN000007408). The expressions of excision repair cross-complementing-1 (ERCC1), class III beta-tubulin, breast cancer susceptibility gene I (BRCA1), and thymidylate synthase were investigated simultaneously in the pre-treatment endoscopic tumor biopsy samples.ResultsA multivariate logistic regression analysis indicated that pathological responses were significantly associated with tumors with low ERCC1 expression (P= 0.016) and with tumors with high BRCA1 expression (P= 0.030). The multivariate Cox proportional hazard model analysis for relapse-free survival revealed high BRCA1 expression (P= 0.031, hazards ratio 4.39) as the factor associated with survival.ConclusionsLow ERCC1 expression and high BRCA1 expression in patients with SCCE were associative biomarkers for chemotherapeutic efficacy. High BRCA1 expression was considered the factor associated with survival. These findings may be helpful for tailoring chemotherapy.